Expression and correlation of microRNA-218 in prostate cancer tissues and serum
10.3760/cma.j.issn.1008-1372.2019.01.020
- VernacularTitle:MicroRNA-218在前列腺癌组织与血清中的表达及相关性研究
- Author:
Lei WANG
1
;
Guangzhou CHENG
;
Dongrong YANG
;
Yuanyuan LIU
;
Qinglei ZHANG
;
Wenyu ZHANG
Author Information
1. 山东省滕州市中心人民医院泌尿外科 277500
- Keywords:
MicroRNAs;
Prostatic neoplasms;
Neoplasms;
hormone-dependent;
Prostatic hyperplasia
- From:
Journal of Chinese Physician
2019;21(1):76-80
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate and explore expression status of microRNA-218,and their correlation in serum and tissue samples of prostate cancer patients.Methods The serum and tissue samples of 72 patients in first diagnosised prostate cancer (PCa) and 80 benign prostate hyperplasia (BPH) patients were collected.Serum samples of 162 patients,including 86 patients with androgen-dependent prostate cancer (ADPC) and 76 patients with hormone-refractory prostate cancer (HRPC) were collected.The expression level of microRNA-218 in the tissue and serum samples were detected by specific SYBR Green quantitative real-time polymerase chain reaction (PCR).The correlation between the serum microRNAs and tissue microRNAs expressions tatus were analyzed,and their relationship with clinical characterization were also analyzed.Results The expression level of microRNA-218 in tissues and serum of patients with BPH was higher than that of patients with PCa (P ≤0.001).MicroRNA-218 level in PCa and BPH tissue were both correlated with that in the serum of PCa and BPH (rBPH =0.815,rPCa =0.423).The expression level of microRNAs in tissue and serum samples from PCa were negatively correlated to total prostate specific antigen (tPSA),clinical stages and pathological grade (P ≤0.05).Serum microRNA-218 expression was not significantly different between hormone-dependent PCa patients and newly diagnosed PCa patients,but was significantly lower than that of HRPC patients (P ≤ 0.05),and was positively correlated with tPSA (P ≤0.05).Conclusions The changes of microRNA-218 expression in serum of patients with BPH and prostate cancer can reflect the changes of microRNA-218 expression in tissues.Serum microRNA-218 is expected to be a potential biomarker for early diagnosis and progression of prostate cancer.
